Peptide pools for SARS-CoV-2–specific T cell research

The scientific community is working at full speed to fight severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Miltenyi Biotec is committed to assisting those researchers in getting to the bottom of SARS‑CoV‑2. 

SARS‑CoV‑2 PepTivator® Peptide Pools

Our newly developed SARS-CoV-2 PepTivator Peptide Pools can be used to load antigen-presenting cells and to stimulate SARS-CoV-2–specific T cells. The T cells can then be detected and/or isolated for further research. We provide four different peptide pools, covering the sequence of three major structural SARS-CoV-2 proteins.

video preview Play video


SARS‑CoV‑2 PepTivator Peptide Pools – a short introduction

Get to know our new products with this video! 

See how the SARS‑CoV‑2 PepTivator Peptide Pools work, which sequences they cover, and how they can potentially be applied in COVID-19 research.

If you are interested in virus-specific PepTivator Products besides SARS-CoV-2, please have a look here.

Exemplary application data of SARS‑CoV‑2 PepTivator Peptide Pools

Detection of SARS-CoV-2–specific T cells in recovered COVID-19 patients

View details

Recovered COVID-19 patients show elevated levels of IFN-γ–producing T cells upon stimulation with SARS‑CoV‑2 PepTivator Peptide Pools

Stimulation with SARS-CoV-2 PepTivator Peptide Pools shows the presence of virus-specific T cells in recovered COVID-19 patients. After stimulation with the peptide pools, intracellular IFN-γ was stained and analyzed in CD3+ T cells using flow cytometry. 

View details

Exemplary quantitative analysis of SARS‑CoV‑2–specific T cells

Quantitative analysis of SARS‑CoV‑2–specific T cells highlights that the highest numbers of activated T cells can be observed when SARS-CoV-2 PepTivators Prot_N, Prot_M, and Prot_S are combined.  

Enrichment of SARS-CoV-2–specific T cells 

View details

Exemplary enrichment of SARS‑CoV‑2–specific T cells  

Rare SARS‑CoV‑2–specific T cells can be enriched using Rapid antigen-specific T cell enrichment (Rapid ARTE). Samples were stimulated with mixed SARS‑CoV‑2 PepTivators, stained (CD3, CD4, CD8, CD154, and TNF-α), and enriched based on the Rapid ARTE protocol.  

Data are kindly provided by Alexander Scheffold and Petra Bacher, UKSH, Kiel, Germany. 

Please note that data are derived from a single experiment and do not include multiple donors. Thus, the results should be considered as exemplary only and not as representative. Results may vary dependent on donor, time since infection, and used assays. 

Related documents:

Selected references

  • Anft, M. et al. (2020) COVID-19 progression is potentially driven by T cell immunopathogenesis. medRxiv 2020.04.28.20083089. Unrefereed preprint.
  • Haun, B.K. et al. (2020) CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation. bioRxiv 2020.07.24.220715. Unrefereed preprint.
  • Kusnadi, A. et al. (2020) Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8+ T cells. bioRxiv 2020.07.09.194027. Unrefereed preprint.
  • Leung, W. et al. (2020) Successful manufacturing of clinical-grade SARS-CoV-2 specific T cells for adoptive cell therapy. medRxiv 2020.04.24.20077487. Unrefereed preprint.
  • Meckiff, B. J. et al. (2020) Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T cells. bioRxiv 2020.06.12.148916. Unrefereed preprint.
  • Sekine, T. et al. (2020) Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. bioRxiv 2020.06.29.174888. Unrefereed preprint.
  • Singh, D. K. et al. (2020) SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species. bioRxiv 2020.06.05.136481. Unrefereed preprint.
  • Thieme, C.J. et al. (2020) The SARS-CoV-2 T cell immunity is directed against the spike, membrane, and nucleocapsid protein and associated with COVID-19 severity. medRxiv 2020.05.13.20100636. Unrefereed preprint.

If you are interested in the SARS‑CoV‑2 PepTivator Peptide Pools, please fill in the contact form below and we will come back to you:

Please select the SARS-CoV-2 PepTivators you are interested in

General Information

Detailed Information

Please give your details for further inquiries.

* Mandatory field

Questions / Comments